Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.
Zheng B, Tazare J, Nab L, Green AC, Curtis HJ, Mahalingasivam V, Herrett EL, Costello RE, Eggo RM, Speed V, Bacon SC, Bates C, Parry J, Cockburn J, Hester F, Harper S, Schaffer AL, Hulme WJ, Mehrkar A, Evans SJ, MacKenna B, Goldacre B, Douglas IJ, Tomlinson LA; OpenSAFELY Collaborative.
Zheng B, et al. Among authors: tomlinson la.
Lancet Reg Health Eur. 2023 Oct 8;34:100741. doi: 10.1016/j.lanepe.2023.100741. eCollection 2023 Nov.
Lancet Reg Health Eur. 2023.
PMID: 37927438
Free PMC article.